Teva Recalls Cephalexin Oral Suspension Due to CGMP Deviations
Teva Pharmaceuticals is recalling Cephalexin for Oral Suspension because current Good Manufacturing Practice deviations may cause active ingredient levels to fall outside specification limits.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which the rubric associates with moderate severity when no specific hospitalizations or injuries are reported, and the hazard is a potential deviation in active ingredient levels.
Plain-English summary
Teva Pharmaceuticals USA is recalling Cephalexin for Oral Suspension, USP 250 mg per 5 mL, in 100 mL and 200 mL bottles. The recall involves 1,467,535 bottles distributed nationwide in the U.S. and Puerto Rico.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. These deviations create a possibility that some bottles in the affected lots may contain the active ingredient at levels above or below the established specification limits.
Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed in the recall notice. Affected products should be returned to the pharmacy or point of purchase for a refund or replacement.
The recalled product
- Product
- CEPHALEXIN (CEPHALEXIN)
- Brand
- CEPHALEXIN
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Antibiotic
- Affected units
- 1,467,535
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #s: a) 30309862A
- 30309863A
- Exp. 08/2020
- 30309928A
- 30309929A
- Exp. 09/2020
- 30310029A
- 30310030A
- 30310033A
- 30310034A
- Exp. 10/2020
- 30310035A
- 30310079A
- 30310080A
- 30310081A
- Exp. 11/2020
- 30310134A
- 30310135A
- Exp. 01/2021
- 30310182A
UPCs (2)
- 0300934175738
- 0300934177732
Distribution
Part of a larger recall action
This product is one of 3 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · CEPHALEXIN
- ModerateCephalexin Oral Suspension Recalled for Failed Impurities Specifications
FDA (Drugs) · 2025-06-18
- ModerateCephalexin Oral Suspension Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-06-18
- ModerateCephalexin oral suspension recalled for incorrect label dosage amount
FDA (Drugs) · 2024-06-12
- ModerateCephalexin oral suspension recalled for incorrect dose labeling
FDA (Drugs) · 2024-06-12
- LowCephalexin for Oral Suspension Recalled for Back Label Error
FDA (Drugs) · 2024-06-12
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19